Uguagliati, Beatrice
  
(2020)
Prenatal treatment with the flavonoid 7,8-DHF improves trisomy-linked proliferation defects in numerous brain regions of the Ts65Dn model of Down syndrome, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. 
 Dottorato di ricerca in 
Scienze biomediche e neuromotorie, 33 Ciclo. DOI 10.6092/unibo/amsdottorato/9537.
  
 
  
  
        
        
        
  
  
  
  
  
  
  
    
  
    
      Documenti full-text disponibili:
      
        
          
            ![Uguagliati_Beatrice_tesi.pdf [thumbnail of Uguagliati_Beatrice_tesi.pdf]](https://amsdottorato.unibo.it/style/images/fileicons/application_pdf.png)  | 
            
              
Documento PDF (English)
 - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
   Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
 
              Download (7MB)
              
			  
			  
              
  
              
             | 
          
        
      
    
  
  
    
      Abstract
      Intellectual disability (ID) is the unavoidable hallmark and the most invalidating feature of DS, a genetic pathology due to triplication of chromosome 21. ID in DS is mainly due to neurodevelopmental alterations among which neurogenesis reduction appears to play a prominent role. Considering the time course of brain development and that the bulk of neurogenesis takes place prenatally, therapeutic interventions aimed at correcting brain developmental defects should be started prenatally. 7,8-DHF is a natural flavonoid that crosses the blood brain barrier, and specifically binds the TrkB receptor activating its downstream signaling cascade. We previously found that neonatal treatment with 7,8-DHF improves cellularity and restores dendritic pathology in the hippocampus of the Ts65Dn mouse, the most studied DS mouse model that largely mimics the human condition. Based on these premises the goal of the current study was to establish whether prenatal treatment with 7,8-DHF is able to rescue overall brain neurogenesis. Ts65Dn pregnant females received 7,8-DHF from embryonic day 10 until delivery. In 2-days-old pups, we evaluated the number of proliferating (BrdU+) cells in various forebrain neurogenic niches. Namely, the rostral and caudal subventricular zone, dentate gyrus, rostral and caudal neocortex, striatum, thalamus and hypothalamus. We found that in treated Ts65Dn mice the proliferation potency was improved or even restored in most of the examined regions. Moreover, treatment restored cellularity in the neocortex layer II but not in the hippocampus. These results show that 7,8-DHF has a positive influence on prenatal neurogenesis and cortical cellularity in the Ts65Dn mouse model, but, unlike neonatal treatment, it has moderate effects on hippocampal cellularity. A treatment with 7,8-DHF that starts embryonically and continues in the early postnatal period should be considered as a promising strategy for the improvement of overall brain development in DS.
     
    
      Abstract
      Intellectual disability (ID) is the unavoidable hallmark and the most invalidating feature of DS, a genetic pathology due to triplication of chromosome 21. ID in DS is mainly due to neurodevelopmental alterations among which neurogenesis reduction appears to play a prominent role. Considering the time course of brain development and that the bulk of neurogenesis takes place prenatally, therapeutic interventions aimed at correcting brain developmental defects should be started prenatally. 7,8-DHF is a natural flavonoid that crosses the blood brain barrier, and specifically binds the TrkB receptor activating its downstream signaling cascade. We previously found that neonatal treatment with 7,8-DHF improves cellularity and restores dendritic pathology in the hippocampus of the Ts65Dn mouse, the most studied DS mouse model that largely mimics the human condition. Based on these premises the goal of the current study was to establish whether prenatal treatment with 7,8-DHF is able to rescue overall brain neurogenesis. Ts65Dn pregnant females received 7,8-DHF from embryonic day 10 until delivery. In 2-days-old pups, we evaluated the number of proliferating (BrdU+) cells in various forebrain neurogenic niches. Namely, the rostral and caudal subventricular zone, dentate gyrus, rostral and caudal neocortex, striatum, thalamus and hypothalamus. We found that in treated Ts65Dn mice the proliferation potency was improved or even restored in most of the examined regions. Moreover, treatment restored cellularity in the neocortex layer II but not in the hippocampus. These results show that 7,8-DHF has a positive influence on prenatal neurogenesis and cortical cellularity in the Ts65Dn mouse model, but, unlike neonatal treatment, it has moderate effects on hippocampal cellularity. A treatment with 7,8-DHF that starts embryonically and continues in the early postnatal period should be considered as a promising strategy for the improvement of overall brain development in DS.
     
  
  
    
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Uguagliati, Beatrice
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          33
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Down syndrome; Ts65Dn; Prenatal neurogenesis; Flavonoids; Pharmacotherapy
          
        
      
        
          URN:NBN
          
          
        
      
        
          DOI
          10.6092/unibo/amsdottorato/9537
          
        
      
        
          Data di discussione
          4 Dicembre 2020
          
        
      
      URI
      
      
     
   
  
    Altri metadati
    
      Tipologia del documento
      Tesi di dottorato
      
      
      
      
        
      
        
          Autore
          Uguagliati, Beatrice
          
        
      
        
          Supervisore
          
          
        
      
        
          Co-supervisore
          
          
        
      
        
          Dottorato di ricerca
          
          
        
      
        
      
        
          Ciclo
          33
          
        
      
        
          Coordinatore
          
          
        
      
        
          Settore disciplinare
          
          
        
      
        
          Settore concorsuale
          
          
        
      
        
          Parole chiave
          Down syndrome; Ts65Dn; Prenatal neurogenesis; Flavonoids; Pharmacotherapy
          
        
      
        
          URN:NBN
          
          
        
      
        
          DOI
          10.6092/unibo/amsdottorato/9537
          
        
      
        
          Data di discussione
          4 Dicembre 2020
          
        
      
      URI
      
      
     
   
  
  
  
  
  
    
    Statistica sui download
    
    
  
  
    
      Gestione del documento: